These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34214373)

  • 1. Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: a retrospective study.
    Nilamsari WP; Rizqi MF; Regina NO; Wulaningrum PA; Fatmawati U
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):783-787. PubMed ID: 34214373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occurrence, Management, and Risk Factors for Adverse Drug Reactions in Multidrug Resistant Tuberculosis Patients.
    Ahmad N; Javaid A; Syed Sulaiman SA; Afridi AK; Zainab ; Khan AH
    Am J Ther; 2018; 25(5):e533-e540. PubMed ID: 26938643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy.
    Gualano G; Mencarini P; Musso M; Mosti S; Santangelo L; Murachelli S; Cannas A; Di Caro A; Navarra A; Goletti D; Girardi E; Palmieri F
    PLoS One; 2019; 14(2):e0212948. PubMed ID: 30817779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Longer the Therapy, the Worse the Severity of the Adverse Drug Reactions that Occur in Drug-Resistant Pulmonary Tuberculosis Patients.
    Susilo R; Azzahra DN; Indawati I; Bachtiar A; Setyaningsih I; Rohadi D; Tomi ; Kustini
    Indian J Tuberc; 2024; 71 Suppl 1():S97-S100. PubMed ID: 39067964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse drug reactions and risk factors for discontinuation of multidrug-resistant tuberculosis regimens in Gujarat, western India.
    Rupani MP; Dave JD; Parmar VB; Singh MP; Parikh KD
    Natl Med J India; 2020; 33(1):10-14. PubMed ID: 33565479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse drug reactions & drug interactions in MDR-TB patients.
    Gupta A; Kumar V; Natarajan S; Singla R
    Indian J Tuberc; 2020 Dec; 67(4S):S69-S78. PubMed ID: 33308674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
    Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical factors associated with utilisation of ototoxicity monitoring services for multi-drug-resistant tuberculosis patients in the Western Cape.
    Ramma L; Nhokwara PT; Rogers C
    S Afr J Commun Disord; 2019 Jan; 66(1):e1-e6. PubMed ID: 30843411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycobacterium tuberculosis resistance pattern against first-line drugs in patients from urban area.
    Cucunawangsih ; Wiwing V; Widysanto A; Lugito NP
    Int J Mycobacteriol; 2015 Dec; 4(4):302-5. PubMed ID: 26964812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [THE FREQUENCIES AND MANAGEMENT OF ADVERSE REACTIONS IN MULTI-DRUG RESISTANT TUBERCULOSIS TREATMENT].
    Sasaki Y; Yoshiyama T; Okumura M; Morimoto K; Miyamoto M; Irina ; Yoshimori K; Kurashima A; Ogata H; Gotoh H
    Kekkaku; 2017 Jan; 92(1):11-19. PubMed ID: 30646468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
    Shibeshi W; Sheth AN; Admasu A; Berha AB; Negash Z; Yimer G
    BMC Pharmacol Toxicol; 2019 May; 20(1):31. PubMed ID: 31122273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug-resistant tuberculosis of the spine--is it the beginning of the end? A study of twenty-five culture proven multidrug-resistant tuberculosis spine patients.
    Pawar UM; Kundnani V; Agashe V; Nene A; Nene A
    Spine (Phila Pa 1976); 2009 Oct; 34(22):E806-10. PubMed ID: 19829244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of antituberculosis agents used for multidrug-resistant tuberculosis among patients attending the Jamot Hospital of Yaounde, Cameroon.
    Mpoh MM; Deli V; Daniel TT; Salvo F
    Int J Mycobacteriol; 2023; 12(2):168-174. PubMed ID: 37338479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH; Kang BH; Lee T; Lee HK; Jang HJ; Cho YJ; Jeon D
    J Korean Med Sci; 2017 Apr; 32(4):636-641. PubMed ID: 28244290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study.
    Yang TW; Park HO; Jang HN; Yang JH; Kim SH; Moon SH; Byun JH; Lee CE; Kim JW; Kang DH
    Medicine (Baltimore); 2017 Jul; 96(28):e7482. PubMed ID: 28700490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse drug reactions in tuberculosis and management.
    Prasad R; Singh A; Gupta N
    Indian J Tuberc; 2019 Oct; 66(4):520-532. PubMed ID: 31813444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse Events Associated With the Treatment of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-analysis.
    Wu S; Zhang Y; Sun F; Chen M; Zhou L; Wang N; Zhan S
    Am J Ther; 2016; 23(2):e521-30. PubMed ID: 24284652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia.
    Buziashvili M; Mirtskhulava V; Kipiani M; Blumberg HM; Baliashvili D; Magee MJ; Furin JJ; Tukvadze N; Kempker RR
    Int J Tuberc Lung Dis; 2019 Sep; 23(9):1005-1011. PubMed ID: 31615608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.